Balkwill F, Mantovani A
ICRF Translational Oncology Laboratory, St Bartholomew's and Royal London School of Medicine and Dentistry, UK.
Lancet. 2001 Feb 17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0.
The response of the body to a cancer is not a unique mechanism but has many parallels with inflammation and wound healing. This article reviews the links between cancer and inflammation and discusses the implications of these links for cancer prevention and treatment. We suggest that the inflammatory cells and cytokines found in tumours are more likely to contribute to tumour growth, progression, and immunosuppression than they are to mount an effective host antitumour response. Moreover cancer susceptibility and severity may be associated with functional polymorphisms of inflammatory cytokine genes, and deletion or inhibition of inflammatory cytokines inhibits development of experimental cancer. If genetic damage is the "match that lights the fire" of cancer, some types of inflammation may provide the "fuel that feeds the flames". Over the past ten years information about the cytokine and chemokine network has led to development of a range of cytokine/chemokine antagonists targeted at inflammatory and allergic diseases. The first of these to enter the clinic, tumour necrosis factor antagonists, have shown encouraging efficacy. In this article we have provided a rationale for the use of cytokine and chemokine blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemoprevention and treatment of malignant diseases.
机体对癌症的反应并非一种独特机制，而是与炎症和伤口愈合有许多相似之处。本文综述了癌症与炎症之间的联系，并讨论了这些联系对癌症预防和治疗的意义。我们认为，肿瘤中发现的炎性细胞和细胞因子更有可能促进肿瘤生长、进展和免疫抑制，而不是引发有效的宿主抗肿瘤反应。此外，癌症易感性和严重程度可能与炎性细胞因子基因的功能多态性有关，炎性细胞因子的缺失或抑制可抑制实验性癌症的发展。如果基因损伤是点燃癌症之火的“火柴”，那么某些类型的炎症可能提供“助燃的燃料”。在过去十年中，有关细胞因子和趋化因子网络的信息促使人们开发出一系列针对炎症和过敏性疾病的细胞因子/趋化因子拮抗剂。首批进入临床的肿瘤坏死因子拮抗剂已显示出令人鼓舞的疗效。在本文中，我们为细胞因子和趋化因子阻断以及非甾体抗炎药在恶性疾病化学预防和治疗中的进一步研究提供了理论依据。
